Yahoo

Apellis' drug better than Soliris in improving hemoglobin levels in trial

(Reuters) - Apellis Pharmaceuticals Inc said on Tuesday its experimental drug for a blood disorder showed greater improvement in patients' hemoglobin levels than market leader Alexion Pharmaceuticals ...
FiercePharma

Alexion scores 2nd FDA nod for Soliris successor drug as switching campaign continues

With a patent challenge for blockbuster Soliris underway, Alexion is working hard to expand the reach of its successor drug Ultomiris. With one carry-over indication already in the bag, Ultomiris just ...
Hartford Business

Alexion’s Soliris drug gets orphan status

Alexion Pharmaceuticals said it has won an orphan-drug designation from the U.S. Food and Drug Administration for its commercial drug Soliris. Orphan drug designations are meant to incentivize ...
Healio

FDA grants orphan drug designation to Soliris tp prevent delayed graft function in kidney transplant patients

Please provide your email address to receive an email when new articles are posted on . The U.S. Food and Drug Administration has granted an orphan drug designation to Alexion Pharmaceuticals' Soliris ...
FiercePharma

FDA Grants Orphan Drug Designation to Soliris(R) (eculizumab) for Prevention of Delayed Graft Function (DGF) in Renal Transplant Patients

FDA Grants Orphan Drug Designation to Soliris(R) (eculizumab) for Prevention of Delayed Graft Function (DGF) in Renal Transplant Patients Alexion Pharmaceuticals (Nasdaq:ALXN) today announced that the ...
GEN

FDA Clears Alexion’s Soliris for All Patients with Atypical Hemolytic Uremic Syndrome

EMA committee separately recommended approval of drug for same indication in Europe. FDA approved Alexion Pharmaceuticals’ Soliris™ (eculizumab) for the treatment of pediatric and adult patients with ...
Hartford Business

Cheshire firm's Soliris drug lauded

Leerink Swann analyst Howard Liang reaffirmed an "outperform" rating for Cheshire-based Alexion Pharmaceuticals Inc. today, citing the future revenue potential for its key drug Soliris. Soliris, ...
Monthly Prescribing Reference

Soliris Designated Orphan Drug for Prevention of Delayed Graft Function

Alexion announced that the FDA has granted Orphan Drug designation to Soliris (eculizumab), a first-in-class terminal complement inhibitor for the prevention of delayed graft function (DGF) in renal ...
AOL

Alexion's Soliris® (eculizumab) Receives Orphan Drug Designation for the Treatment of Neuromyelitis

CHESHIRE, Conn.--(BUSINESS WIRE)-- Alexion Pharmaceuticals, Inc. (NAS: ALXN) today announced that Soliris ® (eculizumab), the company's first-in-class terminal complement inhibitor, has been granted ...
CBS News

FDA okays orphan drug Soliris for deadly blood disease

(CBS) The FDA has approved the drug Soliris (eculizumab) for the treatment of a rare and potentially deadly blood disease known as atypical hemolytic uremic syndrome (aHUS). There are no other ...
Monthly Prescribing Reference

Soliris Gains Orphan Drug Designation for Rare Neurological Disorder

Alexion announced that Soliris (eculizumab), a first-in-class terminal complement inhibitor, has been granted an Orphan Drug designation by the FDA for the treatment of neuromyelitis optica (NMO), a ...